• Analyst Coverage
• Corporate Governance
• Email Alerts
• FAQ
• Financial Reports
• Fundamentals
• Image Library
• Information Request
• Investor Events
• SEC Filings
• Presentation Archive
• Press Releases
• Stock Chart
• Stock Quote
• Worth Noting

Current | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000

David Block Appointed Executive Vice President of Celera and Chief Operating Officer of Celera's Therapeutics Business
Dr. Block to lead Business Development, Strategic Partnership Effort for Therapeutics Business

Rockville, MD - January 07, 2002

Celera Genomics (NYSE: CRA), an Applera Corporation business, announced today that David S. Block, M.D., M.B.A., has been appointed executive vice president of Celera and chief operating officer of Celera’s therapeutics business. Dr. Block will join Celera on February 1, 2002 and will report to J. Craig Venter, Ph.D., Celera’s president and chief scientific officer. Celera also announces the departure of Peter Barrett, Ph.D., who served as executive vice president and chief business officer of Celera.

In this new position, Dr. Block will be primarily responsible for the continued development and execution of Celera’s strategic plan to build its biopharmaceutical business. He will coordinate and expedite the organization’s therapeutic program including potential merger and acquisition activities, the formation and growth of strategic business alliances, as well as direct future licensing agreements.

”We believe the wealth of pharmaceutical business experience that David brings will greatly benefit Celera as it continues its evolution and growth as a therapeutic discovery and development company,” said Dr. Venter. “We look forward to his strategic contributions and leadership in our business development and partnership efforts.” He added, “The growth and success of Celera to this point has been in part due to the dedication of Peter Barrett. We thank him for his more than twenty years of service to the Applera Corporation and for his contributions to the formation and evolution of Celera. We wish him the best in his new endeavor.”

Dr. Block has been with DuPont Pharmaceuticals Company in Wilmington, Delaware for the past 12 years. In his most recent position there he was executive vice president for international operations with direct accountability for all personnel and sales outside the United States. Prior to this he was senior vice president for business development activities; brought to closure numerous collaborations, licensing agreements, and acquisitions; and led the commercialization of Sustiva®, now the most widely used potent HIV agent worldwide.

“Celera has continued to expand and refine its focus into the biopharmaceutical discovery arena over the last year,” noted Tony L. White, chairman, president and chief executive officer of Applera Corporation. “We believe that the pharmaceutical business expertise that David has will be invaluable to the continued success and development of Celera therapeutics business.”

About Applera Corporation and Celera Genomics
Applera Corporation comprises two operating groups. The Celera Genomics Group, headquartered in Rockville, MD, is engaged principally in integrating advanced technologies to create therapeutic discovery and development capabilities for internal use and for its customers and collaborators. Celera’s businesses are its online information business and its therapeutics discovery business. The online information business is a leading provider of information based on the human genome and other biological and medical information. Through the therapeutic discovery business, Celera intends to leverage its genomic and proteomic capabilities to identify drug targets and diagnostic marker candidates, and to discover novel therapeutic candidates. The Applied Biosystems Group (NYSE:ABI) develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.6 billion during fiscal 2001. Celera Diagnostics has been established as a joint venture between Applied Biosystems and Celera Genomics. This new venture is focused on discovery, development and commercialization of novel diagnostic tests. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available on the World Wide Web at www.applera.com, or by telephoning 800.762.6923. Information about Celera is available on the World Wide Web at www.celera.com.

Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.